Does the media prefer NTRA or HALO?

In the previous week, Natera had 6 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 19 mentions for Natera and 13 mentions for Halozyme Therapeutics. Natera's average media sentiment score of 1.21 beat Halozyme Therapeutics' score of 1.20 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HALO or RVMD?

In the previous week, Halozyme Therapeutics and Halozyme Therapeutics both had 13 articles in the media. Halozyme Therapeutics' average media sentiment score of 1.20 beat Revolution Medicines' score of 1.20 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to HALO or BIIB?

In the previous week, Halozyme Therapeutics had 2 more articles in the media than Biogen. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 11 mentions for Biogen. Halozyme Therapeutics' average media sentiment score of 1.20 beat Biogen's score of 1.10 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HALO or ALNY?

In the previous week, Alnylam Pharmaceuticals had 1 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 13 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.20 beat Alnylam Pharmaceuticals' score of 1.12 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer INSM or HALO?

In the previous week, Halozyme Therapeutics had 2 more articles in the media than Insmed. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 11 mentions for Insmed. Halozyme Therapeutics' average media sentiment score of 1.20 beat Insmed's score of 1.15 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Halozyme Therapeutics (HALO) Competitors

$107.20 +0.20 (+0.19%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$106.32 -0.88 (-0.82%)

As of 09/11/2026 07:30 PM Eastern

Compare

HALO vs. NTRA, RVMD, BIIB, ALNY, and INSM

Should you buy Halozyme Therapeutics stock or one of its competitors? Halozyme Therapeutics's main competitors and comparable companies include Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), and Insmed (INSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Halozyme Therapeutics compare to Natera?

Natera (NASDAQ:NTRA) and Halozyme Therapeutics (NASDAQ:HALO) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

Halozyme Therapeutics has lower revenue, but higher earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.56	-$208.16M	-$1.36	N/A
Halozyme Therapeutics	$1.40B	8.71	$316.89M	$3.35	32.00

Halozyme Therapeutics has a net margin of 24.86% compared to Natera's net margin of -7.11%. Halozyme Therapeutics' return on equity of 260.98% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Halozyme Therapeutics	24.86%	260.98%	23.91%

99.9% of Natera shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 5.1% of Natera shares are held by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Natera has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

In the previous week, Natera had 6 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 19 mentions for Natera and 13 mentions for Halozyme Therapeutics. Natera's average media sentiment score of 1.21 beat Halozyme Therapeutics' score of 1.20 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Natera currently has a consensus price target of $330.83, suggesting a potential upside of 0.58%. Halozyme Therapeutics has a consensus price target of $91.20, suggesting a potential downside of 14.93%. Given Natera's stronger consensus rating and higher possible upside, research analysts clearly believe Natera is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Summary

Natera beats Halozyme Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Revolution Medicines?

Halozyme Therapeutics (NASDAQ:HALO) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Halozyme Therapeutics currently has a consensus target price of $91.20, suggesting a potential downside of 14.93%. Revolution Medicines has a consensus target price of $226.17, suggesting a potential upside of 10.99%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Revolution Medicines is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95

In the previous week, Halozyme Therapeutics and Halozyme Therapeutics both had 13 articles in the media. Halozyme Therapeutics' average media sentiment score of 1.20 beat Revolution Medicines' score of 1.20 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Halozyme Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

Halozyme Therapeutics has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.71	$316.89M	$3.35	32.00
Revolution Medicines	N/A	N/A	-$1.13B	-$8.82	N/A

Halozyme Therapeutics has a net margin of 24.86% compared to Revolution Medicines' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Revolution Medicines	N/A	-88.20%	-57.85%

Summary

Halozyme Therapeutics beats Revolution Medicines on 9 of the 15 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Biogen?

Halozyme Therapeutics (NASDAQ:HALO) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Halozyme Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market.

In the previous week, Halozyme Therapeutics had 2 more articles in the media than Biogen. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 11 mentions for Biogen. Halozyme Therapeutics' average media sentiment score of 1.20 beat Biogen's score of 1.10 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Biogen has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.71	$316.89M	$3.35	32.00
Biogen	$9.89B	3.24	$1.29B	$5.65	38.43

Halozyme Therapeutics has a net margin of 24.86% compared to Biogen's net margin of 8.32%. Halozyme Therapeutics' return on equity of 260.98% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Biogen	8.32%	11.18%	6.88%

Halozyme Therapeutics currently has a consensus price target of $91.20, suggesting a potential downside of 14.93%. Biogen has a consensus price target of $230.14, suggesting a potential upside of 5.98%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Summary

Halozyme Therapeutics beats Biogen on 10 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Alnylam Pharmaceuticals?

Halozyme Therapeutics (NASDAQ:HALO) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Halozyme Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

Halozyme Therapeutics has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.71	$316.89M	$3.35	32.00
Alnylam Pharmaceuticals	$3.71B	8.96	$313.75M	$5.38	46.22

In the previous week, Alnylam Pharmaceuticals had 1 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 13 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.20 beat Alnylam Pharmaceuticals' score of 1.12 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics presently has a consensus target price of $91.20, suggesting a potential downside of 14.93%. Alnylam Pharmaceuticals has a consensus target price of $376.67, suggesting a potential upside of 51.47%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Halozyme Therapeutics has a net margin of 24.86% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Halozyme Therapeutics' return on equity of 260.98% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Summary

Alnylam Pharmaceuticals beats Halozyme Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and Halozyme Therapeutics (NASDAQ:HALO) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Insmed currently has a consensus target price of $205.52, indicating a potential upside of 58.81%. Halozyme Therapeutics has a consensus target price of $91.20, indicating a potential downside of 14.93%. Given Insmed's stronger consensus rating and higher probable upside, equities analysts plainly believe Insmed is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

97.8% of Halozyme Therapeutics shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Halozyme Therapeutics had 2 more articles in the media than Insmed. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 11 mentions for Insmed. Halozyme Therapeutics' average media sentiment score of 1.20 beat Insmed's score of 1.15 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has a net margin of 24.86% compared to Insmed's net margin of -76.94%. Halozyme Therapeutics' return on equity of 260.98% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Halozyme Therapeutics	24.86%	260.98%	23.91%

Insmed has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Halozyme Therapeutics has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$1.14B	24.84	-$1.28B	-$4.11	N/A
Halozyme Therapeutics	$1.40B	8.71	$316.89M	$3.35	32.00

Summary

Halozyme Therapeutics beats Insmed on 12 of the 17 factors compared between the two stocks.

Get Halozyme Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HALO vs. The Competition

Export

Metric	Halozyme Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.14B	$3.85B	$7.15B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	32.00	14.18	274.95	25.29
Price / Sales	8.71	1,477.55	656.56	98.96
Price / Cash	22.43	106.68	77.04	51.44
Price / Book	255.24	15.12	10.33	6.20
Net Income	$316.89M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-2.71%	-4.34%	-3.32%	-2.35%
1 Month Performance	5.31%	-0.02%	-0.41%	-2.77%
1 Year Performance	39.40%	40.64%	19.21%	7.63%

Halozyme Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HALO Halozyme Therapeutics	3.1791 of 5 stars	$107.20 +0.2%	$91.20 -14.9%	+38.3%	$12.14B	$1.40B	32.00	423	Positive News Insider Trade
NTRA Natera	2.1538 of 5 stars	$321.96 -1.3%	$319.38 -0.8%	+89.2%	$47.03B	$2.31B	N/A	6,140	Positive News Analyst Forecast
RVMD Revolution Medicines	2.9753 of 5 stars	$205.57 -1.1%	$200.74 -2.4%	+340.7%	$44.56B	$11.58M	N/A	250	Positive News Analyst Forecast Insider Trade
BIIB Biogen	3.2678 of 5 stars	$216.65 -0.8%	$227.79 +5.1%	+45.9%	$32.28B	$10.03B	38.35	7,500	Positive News Analyst Forecast Gap Down
ALNY Alnylam Pharmaceuticals	4.4566 of 5 stars	$240.69 +1.5%	$386.14 +60.4%	-46.9%	$31.73B	$4.80B	44.74	2,770	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HALO) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Halozyme Therapeutics (HALO) Competitors

HALO vs. NTRA, RVMD, BIIB, ALNY, and INSM

How does Halozyme Therapeutics compare to Natera?

Summary

How does Halozyme Therapeutics compare to Revolution Medicines?

Summary

How does Halozyme Therapeutics compare to Biogen?

Summary

How does Halozyme Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does Halozyme Therapeutics compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO vs. The Competition

Halozyme Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Halozyme Therapeutics (HALO) Competitors

HALO vs. NTRA, RVMD, BIIB, ALNY, and INSM

How does Halozyme Therapeutics compare to Natera?

Which has higher earnings and valuation, NTRA or HALO?

Is NTRA or HALO more profitable?

Do institutionals and insiders believe in NTRA or HALO?

Which has more volatility & risk, NTRA or HALO?

Does the media prefer NTRA or HALO?

Do analysts prefer NTRA or HALO?

Summary

How does Halozyme Therapeutics compare to Revolution Medicines?

Do institutionals & insiders have more ownership in HALO or RVMD?

Do analysts prefer HALO or RVMD?

Does the media favor HALO or RVMD?

Which has more volatility and risk, HALO or RVMD?

Which has preferable earnings and valuation, HALO or RVMD?

Is HALO or RVMD more profitable?

Summary

How does Halozyme Therapeutics compare to Biogen?

Which has more risk and volatility, HALO or BIIB?

Does the media refer more to HALO or BIIB?

Do insiders & institutionals hold more shares of HALO or BIIB?

Which has better earnings and valuation, HALO or BIIB?

Is HALO or BIIB more profitable?

Do analysts recommend HALO or BIIB?

Summary

How does Halozyme Therapeutics compare to Alnylam Pharmaceuticals?

Which has more risk & volatility, HALO or ALNY?

Which has higher valuation and earnings, HALO or ALNY?

Does the media refer more to HALO or ALNY?

Do analysts recommend HALO or ALNY?

Do insiders and institutionals hold more shares of HALO or ALNY?

Is HALO or ALNY more profitable?

Summary

How does Halozyme Therapeutics compare to Insmed?

Do analysts rate INSM or HALO?

Do insiders & institutionals have more ownership in INSM or HALO?

Does the media prefer INSM or HALO?

Is INSM or HALO more profitable?

Which has more risk & volatility, INSM or HALO?

Which has better valuation & earnings, INSM or HALO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO vs. The Competition

Halozyme Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools